In this illuminating episode of 'Policy Pod', Giles engages in a captivating conversation with Professor Andrew Cruden, who is a member of the Institute for Life Sciences, Southampton Marine and Maritime Institute, and Energy Technology Group. Professor Cruden introduces to us their groundbreaking FEVER project, which is dedicated to the development and demonstration of a fully autonomous, cost-effective, and socially embraced electric vehicle charger powered by renewables.   Get ready to be inspired as Andrew opens up about his educational journey and career trajectory in the fields of mathematics and physics, providing a unique perspective that sets the stage for this enthralling discussion.   For a deeper dive into the FEVER project, make sure to visit their official website at FEVER

For the 4th series of Policy|Pod, we thought we'd shake up the format and introduce you to some of the Public Policy|Southampton team to learn more about their journey to PPS and the role they perform within the team. Keen to know more? You can find about team members (and their favourite catchphrases) here: MEET THE TEAM; ABOUT US PLUS we would love to hear from you about topics you would like to be briefed on contact us with your briefing request on: [email protected]

In this episode Dr Emilia Holland and Dr Simon Fraser talk about how their research will help in understanding when multiple long-term condition multi-morbidity (MLTC-M) becomes ‘burdensome’ and the best opportunities for intervention. Background  A growing number of people are living with several long-term health conditions like diabetes, heart disease, depression or dementia. We call this multiple long-term condition multi-morbidity (MLTC-M). Many things throughout a person’s life influence the chances of developing health conditions. This includes their biology (e.g. age, ethnicity), things that happen to them (e.g. infections, accidents), behaviours (e.g. smoking, diet) and broader experiences (e.g. the environment people grew up in, their education, work, income). People from more disadvantaged backgrounds and/or certain ethnicities are more likely to develop MLTC-M and to develop it earlier. The impact (or ‘burden’) of MLTC-M, and the order that people develop conditions, also vary.  The project page: Research project: Multidisciplinary Ecosystem to study Lifecourse Determinants and Prevention of Early-onset Burdensome Multimorbidity (MELD-B) New publication: A conceptual framework for characterising lifecourse determinants of multiple long-term condition multimorbidity  

Dr Natasha Campling and Professor Sue Latter discuss ways to improve access to medicines and support palliative care at home.  Background-  Patient and carer access to medicines during the last 12 months of life (end-of-life) is critical for control of symptoms, including pain and distress, and for reducing urgent, unplanned use of healthcare services. However, data from our previous studies suggested that prescription, dispensing, supply and associated information given about medicines are experienced by patients as often difficult, demanding, lacking co-ordination, and involves a multiplicity of professionals. Although evidence is suggestive of patient and carer access problems with traditional service delivery systems, including General Practitioner care, little is known about this. Additionally, there are indications that critical sectors of the end-of-life workforce – palliative care nurse specialists and community pharmacists - are currently under-utilised. Furthermore, whilst there are some promising innovations in end-of-life care models, the impact of these on patient access to medicines, as well as their cost-effectiveness comparative to more traditional delivery models, remains largely un-evaluated. Our recent research also suggests that the supply chain ‘upstream’ may be a contributing factor to the complexity and problems with access experienced by patients.      

In this episode Dr Chrissie Jones talks about how traditionally, pregnant women have been excluded from research regarding interventional trials and educational strategies related to preventing infections during pregnancy.